Affimed N.V.
NASDAQ:AFMD
| Market Cap (Intraday) | 964.13M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.39 |
| 50-Day MA | $9.35 |
| 200-Day MA | $6.25 |
Affimed N.V. Stock, NASDAQ:AFMD
Technologiepark, Im Neuenheimer Feld 582, Heidelberg, Baden Wuerttemberg 69120
Germany
Phone: +49.6221.6743.60
Number of Employees: 163
Description
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.